(Q51576819)

7 April 2018

title

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. (English)

1 reference

7 April 2018

main subject

phase I clinical trial

0 references

angiogenesis inhibitor

1 reference

2

Laurence Albiges-Sauvin

0 references

Isabelle Brocheriou

9

object named as

Isabelle Brocheriou-Spelle

0 references

Jean-Charles Soria

10

object named as

Jean-Charles Soria

0 references

author name string

Antonin Levy

1

1 reference

7 April 2018

Laurence Albiges-Sauvin

2

1 reference

7 April 2018

Christophe Massard

3

1 reference

7 April 2018

Hassan Izzedine

4

1 reference

7 April 2018

Stéphane Ederhy

5

1 reference

7 April 2018

Ratio Bahleda

6

1 reference

7 April 2018

Carlos Gomez-Roca

7

1 reference

7 April 2018

Cyrus Chargari

8

1 reference

7 April 2018

Isabelle Brocheriou-Spelle

9

1 reference

7 April 2018

Jean-Charles Soria

10

1 reference

7 April 2018

publication date

21 April 2011

1 reference

7 April 2018

Investigational New Drugs

published in

1 reference

7 April 2018

volume

30

1 reference

7 April 2018

issue

3

1 reference

7 April 2018

page(s)

1116-1120

1 reference

7 April 2018

https://scigraph.springernature.com/pub.10.1007/s10637-011-9671-z

exact match

0 references

cites work

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Assessing kidney function--measured and estimated glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9671-Z

Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?

21 January 2018

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

1 reference

12 December 2020

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

12 December 2020

10.1007/S10637-011-9671-Z

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018